1. Home
  2. ZURA vs CBIO Comparison

ZURA vs CBIO Comparison

Compare ZURA & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

N/A

Current Price

$0.97

Market Cap

455.4M

Sector

Health Care

ML Signal

N/A

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$13.19

Market Cap

507.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ZURA
CBIO
Founded
2022
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
507.1M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
ZURA
CBIO
Price
$0.97
$13.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
8
Target Price
$8.00
★ $32.33
AVG Volume (30 Days)
★ 6.7M
205.8K
Earning Date
10-27-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $18,500.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$37.50
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$8.72
52 Week High
$7.25
$27.41

Technical Indicators

Market Signals
Indicator
ZURA
CBIO
Relative Strength Index (RSI) 24.64 44.27
Support Level $0.93 $11.78
Resistance Level $5.97 $13.54
Average True Range (ATR) 0.23 1.08
MACD -0.15 -0.04
Stochastic Oscillator 0.46 23.21

Price Performance

Historical Comparison
ZURA
CBIO

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: